Effect of acute and chronic treatment with methamphetamine on mRNA expression of synaptotagmin IV and 25 KDa-synaptic-associated protein in the rat brain.
The effects of acute and chronic administration of methamphetamine (METH) on mRNA levels of synaptotagmin IV (SytIV) and an isoform of synaptic-associated protein of 25 KDa (SNAP25a) have been investigated in rat brain using in situ hybridization. Pretreatment with 0.5 mg/kg dopamine D1 receptor antagonist (SCH23390), but not 0.5 mg/kg N-methyl-D-aspartate (NMDA) receptor antagonist (MK-801), significantly attenuated the increased SytIV mRNA levels induced by acute METH administration in the striatum and the nucleus accumbens. Pretreatment with 0.5 mg/kg SCH23390, but not 0.5 mg/kg MK-801, significantly attenuated the increased SNAP25a mRNA levels induced by acute METH administration in the striatum and the dentate gyrus of the hippocampus. In the chronic treatment experiment, the SytIV mRNA levels of the group that received chronic treatment with METH followed by a METH challenge showed an increase similar to that seen after acute METH administration. In addition, those in the striatum, nucleus accumbens, and dentate gyrus were significantly higher than those of the group that received chronic treatment with saline followed by a METH challenge. The SNAP25a mRNA levels of the group that received chronic treatment with METH followed by a saline challenge were significantly higher than those of the group that received chronic treatment with saline followed by a saline challenge in the striatum and nucleus accumbens. The results of the present study suggest that SytIV may play an important role in the synaptic plasticity underlying METH-induced neuroadaptive changes including behavioral sensitization.
Isao
Taketo
T
Department of Psychiatry, Dokkyo University School of Medicine, Tochigi, Japan. isao@dokkyomed.ac.jp
Akiyama
Kazufumi
K
D000818:Animals; D001552:Benzazepines / Q000494:pharmacology; D002135:Calcium-Binding Proteins / Q000187:drug effects* / Q000235:genetics*; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D018891:Dentate Gyrus / Q000187:drug effects / Q000378:metabolism; D016291:Dizocilpine Maleate / Q000494:pharmacology; D015870:Gene Expression / Q000187:drug effects; D008134:Long-Term Care; D008562:Membrane Glycoproteins / Q000187:drug effects* / Q000235:genetics*; D008565:Membrane Proteins / Q000187:drug effects* / Q000235:genetics*; D008694:Methamphetamine / Q000633:toxicity*; D009419:Nerve Tissue Proteins / Q000187:drug effects* / Q000235:genetics*; D009473:Neuronal Plasticity / Q000187:drug effects / Q000235:genetics; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism; D020033:Protein Isoforms / Q000187:drug effects* / Q000235:genetics*; D012333:RNA, Messenger / Q000187:drug effects* / Q000235:genetics*; D051381:Rats; D017447:Receptors, Dopamine D1 / Q000037:antagonists & inhibitors; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors; D013566:Sympathomimetics / Q000633:toxicity*; D050825:Synaptosomal-Associated Protein 25; D050857:Synaptotagmins
D001552:Benzazepines; D002135:Calcium-Binding Proteins; D008562:Membrane Glycoproteins; D008565:Membrane Proteins; D009419:Nerve Tissue Proteins; D020033:Protein Isoforms; D012333:RNA, Messenger; D017447:Receptors, Dopamine D1; D016194:Receptors, N-Methyl-D-Aspartate; C494210:Snap25 protein, rat; D013566:Sympathomimetics; D050825:Synaptosomal-Associated Protein 25; C494294:Syt4 protein, rat; D050857:Synaptotagmins; D008694:Methamphetamine; D016291:Dizocilpine Maleate